Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800081 | 0.77 | DRD4 (0.39) | MAPTALDH1A1LMNARAB9A | |
| SCHEMBL6793606 | 0.67 | MAPKAPK2 (0.45) | SMN1; SMN2MAPKAPK2ATMAKR1B1MAPT | |
| SCHEMBL6800726 | 0.65 | POLB (0.41) | ALDH1A1 | |
| SCHEMBL7278994 | 0.65 | SMN1; SMN2 (0.73) | SMN1; SMN2ATMMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11669572 | 0.62 | ATM (0.52) | SMN1; SMN2ATMAKR1B1MAPTALDH1A1 | |
| SCHEMBL11573244 | 0.59 | ALDH1A1 (0.64) | SMN1; SMN2MAPTALDH1A1LMNAHTT | |
| SCHEMBL12177434 | 0.59 | ALDH1A1 (0.71) | SMN1; SMN2AKR1B1ALDH1A1FPR2 | |
| SCHEMBL2607454 | 0.58 | ALDH1A1 (0.71) | ATMAKR1B1MAPTALDH1A1LMNA | |
| SCHEMBL7314984 | 0.58 | ALDH1A1 (0.58) | SMN1; SMN2MAPTALDH1A1LMNAHTT | |
| SCHEMBL1504229 | 0.58 | ALDH1A1 (0.68) | SMN1; SMN2MAPTALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | SMN1; SMN2 1213/4885MAPKAPK2 3594/4885ATM 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.